Mutagenesis in norovirus in response to favipiravir treatment

New England Journal of Medicine

Volumn 379, Issue 22, 2018, Pages 2173-2176

  Ruis, Christopher ^a   Brown, K Li An K ^b   Roy, Sunando ^a   Atkinson, Claire ^a   Williams, Rachel ^a   Burns, Siobhan O ^a   Yara Romero, Erika ^a   Jacobs, Michael ^b   Goldstein, Richard ^a   Breuer, Judith ^a   Lowe, David M ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTIINFECTIVE AGENT; ASPARTATE AMINOTRANSFERASE; FAVIPIRAVIR; GLUCOCORTICOID; IMMUNOGLOBULIN; INFLIXIMAB; LEVOFLOXACIN; LOPERAMIDE; NITAZOXANIDE; RIBAVIRIN; AMIDE; ANTIVIRUS AGENT; PYRAZINE DERIVATIVE;

ADULT; AIRWAY OBSTRUCTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY WEIGHT GAIN; BRONCHIOLITIS; CASE REPORT; CLINICAL ARTICLE; COMMON VARIABLE IMMUNODEFICIENCY; DIARRHEA; DRUG RESPONSE; DRUG WITHDRAWAL; ENTEROPATHY; FECES ANALYSIS; GASTROINTESTINAL SYMPTOM; HUMAN; LACK OF DRUG EFFECT; LETTER; LIVER DYSFUNCTION; MALE; MIDDLE AGED; MUTAGENESIS; NOROVIRUS INFECTION; PARENTERAL NUTRITION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESPIRATORY FAILURE; VIRUS LOAD; CALICIVIRUS INFECTION; CHRONIC DISEASE; COMPLICATION; DRUG EFFECT; FATALITY; GENETICS; ISOLATION AND PURIFICATION; NOROVIRUS;

AMIDES; ANTIVIRAL AGENTS; CALICIVIRIDAE INFECTIONS; CHRONIC DISEASE; COMMON VARIABLE IMMUNODEFICIENCY; DIARRHEA; FATAL OUTCOME; HUMANS; MALE; MIDDLE AGED; MUTAGENESIS; NOROVIRUS; PYRAZINES;

EID: 85057556270     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1806941     Document Type: Letter

References (5)

1. Brown LK, Clark I, Brown JR, Breuer J, Lowe DM. Norovirus infection in primary immune deficiency. Rev Med Virol 2017 March 8 (Epub ahead of print).
2. Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare, Japan. Report on the deliberation results: Avigan tablet 200 mg (favipiravir). March 4, 2014 (https://www.pmda.go.jp/ files/ 000210319.pdf ).
3. Sissoko D, Laouenan C, Folkesson E, et al. Experimental treatment with favipiravir for Ebola virus disease (the JIKI Trial): A historically controlled, single-arm proof-of-concept trial in Guinea. PLoS Med 2016; 13(3): E1001967.
4. Arias A, Thorne L, Goodfellow I. Favipiravir elicits antiviral mutagenesis during virus replication in vivo. Elife 2014; 3: E03679.
5. Brown JR, Roy S, Ruis C, et al. Norovirus whole-genome sequencing by SureSelect target enrichment: A robust and sensitive method. J Clin Microbiol 2016; 54: 2530-7.